Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Yale University, New Haven, Connecticut UF Health Cancer Institute - Gainesville, Gainesville, Florida University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma